Ọgwụ ọhụrụ na-ebelata mgbasa nke ọrịa kansa ara

Nnyocha ahụike e mere n’oge na-adịbeghị anya gosiri na ọgwụ ọhụrụ e ji agwọ ọrịa ara ara pụrụ ibelata ọrịa ahụ ruo ọnwa atọ ma nwee mmetụta dị nta karị.

Nnwale ọgwụ, nke a maara dị ka "TDM1," na-arụ ọrụ megide ụdị ọrịa cancer ara kachasị njọ, na ọgwụ "Herceptin" na-ejikọta ya na chemotherapy n'otu dose, na ule egosiwo na ọgwụ ọhụrụ ahụ na-egbochi ọrịa ara ara dị elu ka ọ ghara ịdị njọ maka ya. ọnwa atọ ma e jiri ya tụnyere ọgwụgwọ ọkọlọtọ.

A na-ewere ọgwụ a dị ka nke mbụ nke ụdị ọrịa cancer ara ma na-arụ ọrụ site na ijikọta akụkụ nke cell carcinogenic ma gbochie ya ịmalite ma gbasaa, ebe ọ na-aga na cell n'otu oge ma na-ahapụ chemotherapy na-egbu egbu n'ime. .

N'ime nnwale nke ihe fọrọ nke nta ka ọ bụrụ 2 ndị nwere ọrịa kansa HER1 dị elu, mmadụ anọ n'ime ndị ọrịa iri zara TDMXNUMX, ma e jiri ya tụnyere ihe na-erughị otu ụzọ n'ụzọ atọ nke ndị nọ na ọgwụgwọ ọkọlọtọ.

Prọfesọ Paul Ellis si Guy's Hospital na London kwuru, sị: 'Nchọpụta ndị a kwesịrị ịrịba ama n'ihi na na nke mbụ na ọrịa kansa ara, anyị enwewo ike imeziwanye nrụpụta ọrụ nke ukwuu ma n'otu oge ahụ na-ebelata ọtụtụ mmetụta ọjọọ ndị na-ejikọta na chemotherapy.

N'akụkụ nke ya, onye isi otu British Breast Cancer Research Society, Dr. Lisa Wild Ọmụmụ ihe a bụ mmepe dị mma maka ndị ọrịa nwere ọrịa kansa ara HER2 nke nwere oke ọgwụgwọ ugbu a.

Ọ dabara nke ọma, ọrịa kansa ara bụ otu n'ime ọrịa cancer nke enwere ike ịgwọ ya kpamkpam ma ọ bụrụ na achọpụtara ya n'oge, nke a bụ ihe anyị na-akpọ maka ụmụ nwanyị niile gafere afọ 25.